Sofosbuvir and Daclatasvir
Buy Sofosbuvir and Daclatasvir Online
Hepatitis C is a viral infection. It can inflame and damage the liver.
Hepatitis C is usually transmitted through contact with infected blood. It can be spread through:
- Shared needles during intravenous drug use
- Shared devices used to snort cocaine
- Unprotected sexual intercourse (this is uncommon)
- Accidental stick with a contaminated needle
- Blood transfusions (rare because of improved screening techniques since 1992)
- Renal dialysis
- Childbirth, from mother to child during delivery
- Contaminated tattoo or body piercing equipment
The hepatitis C virus can cause short-term (acute) or long-term (chronic) hepatitis C. Most people with acute hepatitis C eventually develop chronic hepatitis C.
Most people with hepatitis C don't know that they are infected. That's because hepatitis C usually does not cause symptoms.
After having this silent infection for 20 to 30 years, about one-third of people develop cirrhosis. Cirrhosis is a serious liver disease that can lead to death. A smaller group of people with chronic hepatitis C develop liver cancer.
What is Sofosbuvir and Daclatasvir Tablet?
Daclatasvir is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body.
Daclatasvir is used in combination with other medications to treat chronic hepatitis C in adults.
Daclatasvir treats specific genotypes of hepatitis C, and only in certain people. Use only the medications prescribed for you. Do not share your medicine with other people.
Daclatasvir must be given in combination with other antiviral medications and should not be used alone. Daclatasvir is usually given with sofosbuvir, with or without ribavirin.
Daclatasvir is sometimes used in people who also have HIV. Daclatasvir is not a treatment for HIV or AIDS.
Sofosbuvir is an antiviral medication that prevents hepatitis C virus (HCV) from multiplying in your body.
Sofosbuvir is used in combination with other medications to treat chronic hepatitis C in adults and children who are at least 12 years old or who weigh at least 77 pounds (35 kilograms).
Sofosbuvir treats specific genotypes of hepatitis C, and only in certain people. Use only the medications prescribed for you. Do not share your medicine with other people.
Sofosbuvir must be given in combination with other antiviral medications and should not be used alone. Sofosbuvir is usually given with ribavirin, with or without peginterferon alfa.
Sofosbuvir is sometimes used in people who also have HIV, or people who have liver cancer and are going to have a liver transplant. Sofosbuvir is not a treatment for HIV or AIDS.
How To Take Sofosbuvir and Daclatasvir Tablet?
Daclatasvir - The recommended dose is one tablet once a day of Daclatasvir 60 mg (this dose may vary and will be decided by your doctor). Swallow the tablet whole. Do not chew or crush the tablet as it has an unpleasant taste. Can be taken with or without food.
Sofosbuvir - The recommended dose is one tablet (400mg) once a day with food. Swallow the tablet whole. Do not chew, crush or split the tablet as it has a bitter taste.
Side Effects of Sofosbuvir and Daclatasvir
Daclatasvir, like all other medicines, has some side effects.
Most of these are minor and will settle within a few days or weeks
- Feeling sick (nausea)
Sofosbuvir, like all other medicines, has some side effects.
Most of these are minor and will settle within a few days or weeks.
- Feeling sick (nausea)
- Tiredness and trouble sleeping
- Changes in blood test
Warning And Precaution of Sofosbuvir and Daclatasvir tablet
The concomitant use of Daclactasvir, Sofosbuvir and other drugs may result in known or potentially significant drug interactions, some of which may lead to loss of therapeutic effect of Daclactasvir, Sofosbuvir and possible development of resistance, dosage adjustments of concomitant medications or Daclactasvir, Sofosbuvir,possible clinically significant adverse reactions from greater exposures of concomitant drugs or Daclactasvir, Sofosbuvir.
Drugs contraindicated with Daclactasvir, Sofosbuvir due to loss of efficacy and possible development of resistance for steps to prevent or manage other possible and known significant drug interactions. Consider the potential for drug interactions before and during Daclactasvir, Sofosbuvir therapy, review concomitant medications during Daclactasvir, Sofosbuvir therapy, and monitor for the adverse reactions associated with the concomitant drugs.
Serious Symptomatic Bradycardia When Coadministered With Sofosbuvir And Amiodarone
Postmarketing cases of symptomatic bradycardia and cases requiring pacemaker intervention have been reported when amiodarone is coadministered with sofosbuvir in combination with another HCV direct-acting antiviral, including Daclactasvir, Sofosbuvir.
A fatal cardiac arrest was reported in a patient receiving a sofosbuvir-containing regimen (ledipasvir/sofosbuvir). Bradycardia has generally occurred within hours to days, but cases have been observed up to 2 weeks after initiating HCV treatment.
Patients also taking beta blockers or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone.
Bradycardia generally resolved after discontinuation of HCV treatment. The mechanism for this bradycardia effect is unknown.
Coadministration of amiodarone with Daclactasvir in combination with sofosbuvir is not recommended. For patients taking amiodarone who have no alternative treatment options and who will be coadministered Daclactasvir and sofosbuvir:
Cardiac monitoring in an inpatient setting for the first 48 hours of coadministration is recommended, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment.
Patients who are taking sofosbuvir in combination with Daclactasvir, Sofosbuvir who need to start amiodarone therapy due to no other alternative treatment options should undergo similar cardiac monitoring as outlined above.
Due to amiodarone's long elimination half-life, patients discontinuing amiodarone just prior to starting sofosbuvir in combination with Daclactasvir, Sofosbuvir should also undergo similar cardiac monitoring as outlined above.
Patients who develop signs or symptoms of bradycardia should seek medical evaluation immediately. Symptoms may include near-fainting or fainting, dizziness or lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, confusion, or memory problems.
Risks Associated With Ribavirin Combination Treatment If Daclactasvir and sofosbuvir are administered with ribavirin, the warning and precausion for ribavirin, in particular the pregnancy avoidance warning, apply to this combination regimen. Refer to the ribavirin prescribing information for a full list of the warnings and precautions for ribavirin.
Sofosbuvir and Daclatasvir Dosage
Treatment works best if there is a constant amount of the drugs in your body. It is really important that you take the tablets regularly. However, occasionally you may forget a dose. Don’t worry if this happens, just follow the guidance below. If you are having problems remembering to take your medicines, speak with your clinic nurse and they may be able to help you.
Daclatasvir If you notice within 20 hours of the time you usually take Daclactasvir, you must take the tablet as soon as possible. Then take the next dose at your usual time.
If you notice more than 20 hours after the time you usually take Daclactasvir, wait and take the next dose at your usual time. Do not take a double dose (two doses close together).
Sofosbuvir If you notice within 18 hours of the time you usually take Sofosbuvir, you must take the tablet as soon as possible. Then take the next dose at your usual time.
If you notice 18 hours or more after the time you usually take Sofosbuvir, wait and take the next dose at your usual time. Do not take a double dose (two doses close together).
Safety information about Sofosbuvir and Daclatasvir
It is always important to make your doctor and pharmacist aware of any medicines you take to ensure that they are compatible with your treatment. This includes any recreational, over-the-counter or herbal medications. Before starting any new medications you must check they are safe to take with your clinic nurse, doctor or pharmacist. Important Information You must not stop, or allow anyone else to stop, your treatment unless discussed with the doctor or nurse in charge of your Hepatitis C treatment.
Uses of Sofosbuvir and Daclatasvir
A total of 194 drugs are known to interact with daclatasvir.
- Daclatasvir is in the drug class NS5A inhibitors.
- Daclatasvir is used to treat Hepatitis C.
A total of 30 drugs are known to interact with sofosbuvir.
- Sofosbuvir is a member of the drug class miscellaneous antivirals.
- Sofosbuvir is used to treat Hepatitis C.
Storage of Sofosbuvir and Daclatasvir
There are no special storage instructions for Daclactasvir, Sofosbuvir; however they should be kept in a safe place, away from children.